TY  - JOUR
ID  - arxiv65786
UR  - https://mjstjournal.com/index.php/mjst/article/view/6884
Y1  - 2026/02/22/
KW  - Breast cancer
KW  -  Luminal B
KW  -  Neoadjuvant chemotherapy
KW  -  Ki-67
KW  -  Clinical Oncology
KW  -  Biostatistics
KW  -  Personalized Medicine.
AV  - none
A1  - Sevara, Alimbayeva
A1  - Dilmurod, Axadullayev
A1  - Akhmadjan, Madaminov
N1  - Imported from MJST Journal (OAI id oai:ojs.pkp.sfu.ca:article/6884)
TI  - INTEGRATED THERAPEUTIC STRATEGIES AND PERSONALIZED APPROACHES IN THE MANAGEMENT OF LUMINAL B HER2-NEGATIVE BREAST CANCER: A CLINICAL-STATISTICAL ANALYSIS
PB  - Center for Tech and Media Research
N2  - Breast cancer (BC) remains a leading cause of female morbidity and mortality globally. Modern management has shifted from a "one-size-fits-all" approach to molecular-subtype-driven personalized therapy. This study evaluates the clinical efficacy of dose-dense neoadjuvant chemotherapy (NACT) combined with targeted hormonal maintenance in patients with Luminal B HER2-negative breast cancer (stages IIA-IIIB). Analyzing a cohort of 84 patients, we assessed the objective response rate (ORR) and the frequency of pathological complete response (pCR). Statistical analysis using Student's t-test and $\chi^2$ criteria demonstrated that the integration of taxane-based dose-dense regimens significantly improves surgical outcomes compared to standard FEC protocols ($p < 0.05$). The findings emphasize the necessity of tailoring systemic therapy based on Ki-67 proliferation indices and lymphovascular invasion markers to optimize long-term survival.
JF  - Multidisciplinary Journal of Science and Technology
ER  -